Biologic characteristics of breast cancer detected by mammograpby and by palpation in a screening program: A pilot study

Clinical and Investigative Medicine

Volumn 20, Issue 5, 1997, Pages 300-307

  Tweedie, Edward ^a   Tonkin, Katia ^b   Kerkvliet, Nancy ^a   Doig, Gordon S ^a   Sparrow, R Keith ^a   O'Malley, Frances P ^a,b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER SCREENING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; ONCOGENE C ERB; PALPATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MAMMOGRAPHY; MIDDLE AGED; PALPATION; PILOT PROJECTS; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030780320     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Garfinkel L, Boring CC, Heath CW Jr. Changing trends: an overview of breast cancer incidence and mortality. Cancer 1994;74(1 suppl):222-7.
2. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the international workshop on screening for breast cancer. J Natl Cancer Inst 1993;85(20):1644-56.
3. Shapiro S. Screening: assessment of current studies. Cancer 1994;74(1 suppl):231-8.
4. Toikkanen S, Dean PB, Joensuu H. Screen-detected breast carcinomas - Do they differ from those diagnosed outside screening programs? In: Rosen PP, Rechner RE, editors. Pathology annual vol. 29. Norwalk (CT): Appleton & Lange; 1994. p. 261-78.
5. Anderson TJ, Lamb J, Donnan P, Alexander FE, Huggins A, Muir BB, et al. Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer 1991;64:108-13.
6. Crisp WJ, Higgs MJ, Cowan WK, Cunliffe WJ, Lunt LG, Peakman DJ, et al. Screening for breast cancer detects tumours at an earlier biological stage. Br J Surg 1993;80:863-5.
7. Rajakariar R, Walker RA. Pathological and biological features of mammographically detected invasive breast carcinomas. Br J Cancer 1995;71:150-4.
8. Perrault D, Libstug A, Mercer S, Vayda E. The Ontario Breast Screening Program: the first 18 months. Ont Med Rev 1992;Dec:27-33.
9. Perrault D, Libstug A, Shedden S, Moravan V, Whittick D. The Ontario Breast Screening Program. Ont Med Rev 1994;June:32-6.
10. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osbourne CK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
11. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6.
12. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-14.
13. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-54.
14. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993;85:965-70.
15. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, et al. C-erbB-2 and ras expression levels in breast cancer are correlated and show a cooperative association with unfavorable clinical outcome. Int J Cancer 1991;47:833-8.
16. Elledge RM, Fuqua AW, Clark GM, Pujol P, Allred DC, McGuire WL. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993;26:225-35.
17. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
19. Corbett IP, Henry JA, Angus B, Watchorn CJ, Wilkinson L, Hennessy C, et al. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 1990;161:15-25.
20. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
21. Hsu SM, Raine L, Fanger H. The use of Avidin-Biotin peroxidase complex (ABC) and immunoperoxidase technique: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
22. Foster R Jr, Worden JK, Costanza MC, Solomon LJ. Clinical breast examination and breast self-examination. Cancer 1992;69(7 suppl):1992-8.
23. Miller AS, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. Can Med Assoc J 1992;147:1477-88.
24. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988;297:943-8.
25. Roberts MM, Alexander FE, Anderson TJ, Chetty U, Donnan PT, Forrest P, et al. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet 1990;335:241-6.
26. Page DL. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol 1991;15:334-49.
27. Simpson JF, Page DL. Prognostic value of histopathology in the breast. Semin Oncol 1992;19:254-62.
28. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992;20:479-89.
29. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63(1):181-7.
30. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989;7(3):355-66.
31. Mansour EG, Ravdin PM, Dressier L. Prognostic factors in early breast carcinoma. Cancer 1994;74(1 suppl):381-400.
32. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-country program of mammographic screening for breast cancer. In: Bassett LW, editor. The radiologic clinics of North America: breast imaging, current status and future directions, vol. 30(1). Toronto: WB Saunders; 1992. p. 187-210.
33. Silverstein MJ, Gierson ED, Waisman JR, Colbum WJ, Gamagami P. Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability. J Am Coll Surg 1995;180:700-4.
34. McKinney CD, Frierson HFJ, Fechner RE, Wilhelm MC, Edge SB. Pathologic findings in nonpalpable invasive breast cancer. Am J Surg Pathol 1992;16:33-6.
35. Kallioniemi OP, Karkkainen A, Auvinen O, Mattila J, Koivula T, Hakama M. DNA flow cytometric analysis indicates that many breast cancers detected in the first round of mammographic screening have a low malignant potential. Int J Cancer 1988;42:697-702.
36. Ponten J, Holmberg L, Trichopoulas D, Kallioniemi O, Kvale G. Biology and natural history of breast cancer. Int J Cancer 1990;5(suppl):5-21.
37. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992;326:1756-61.
38. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51:944-8.
39. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowitz M, et al. HER-2/neu expression in node-negative breast cancers: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70.
40. Ro J, El-Nagger A, Ro JY, Blick M, Fraschini F, Pritsche H, et al. c-erb B2 amplification in node negative breast cancer. Cancer Res 1989;49:6941-4.
41. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10(7):1049-56.
42. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12.
43. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma - a detailed morphological analysis. J Pathol 1990;161:7-14.
44. Lane DP, Crawford LV. T-antigen is bound to host protein in SV40 transformed cells. Nature 1979;278:261-3.